Pluripotent and direct reprogramming technologies hold great potential for tissue repair and restoration of tissue and organ function. The implementation of induced pluripotent stem cells and directly reprogrammed cells in biomedical research has resulted in a significant leap forward in the highly promising area of regenerative medicine. While these therapeutic strategies are promising, there are several obstacles to overcome prior to the introduction of these therapies into clinical settings. Bioengineering technologies, such as biomaterials, bioprinting, microfluidic devices, and biostimulatory systems, can enhance cell viability, differentiation, and function, in turn the efficacy of cell therapeutics generated via pluripotent and direct reprogramming. Therefore, cellular reprogramming technologies, in combination with tissue-engineering platforms, are poised to overcome current bottlenecks associated with cell-based therapies and create new ways of producing engineered tissue substitutes.
Bibliographical noteFunding Information:
This work was supported by a grant (No. 2018R1D1A1B07042768) from the National Research Foundation (NRF) of Korea funded by the Ministry of Science and ICT (MSIT), Republic of Korea. This work was also supported by a grant (No. 19172MFDS168) funded by the Ministry of Food and Drug Safety (MFDS).
1Department of Biotechnology, Yonsei University, Seoul 03722, Republic of Korea 2Center for Nanomedicine, Institute for Basic Science (IBS), Seoul 03722, Republic of Korea 3Graduate Program of Nano Biomedical Engineering (NanoBME), Advanced Science Institute, Yonsei University, Seoul 03722, Republic of Korea Note: This paper is part of the special issue on Functional Biomaterials. a)Author to whom correspondence should be addressed: email@example.com
© 2021 Author(s).
All Science Journal Classification (ASJC) codes
- Biomedical Engineering